posted on 2023-04-03, 22:24authored byHaisheng Zhang, Antje Schaefer, Yichen Wang, Richard G. Hodge, Devon R. Blake, J. Nathaniel Diehl, Alex G. Papageorge, Matthew D. Stachler, Jennifer Liao, Jin Zhou, Zhong Wu, Fahire G. Akarca, Leonie K. de Klerk, Sarah Derks, Mariaelena Pierobon, Katherine A. Hoadley, Timothy C. Wang, George Church, Kwok-Kin Wong, Emanuel F. Petricoin, Adrienne D. Cox, Douglas R. Lowy, Channing J. Der, Adam J. Bass
Supplementary Video S1
Funding
NCI
Debbie's Dream Foundation
AACR
NIH
History
ARTICLE ABSTRACT
Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy. Among the most provocative recent results in DGC has been that of highly recurrent missense mutations in the GTPase RHOA. The function of these mutations has remained unresolved. We demonstrate that RHOAY42C, the most common RHOA mutation in DGC, is a gain-of-function oncogenic mutant, and that expression of RHOAY42C with inactivation of the canonical tumor suppressor Cdh1 induces metastatic DGC in a mouse model. Biochemically, RHOAY42C exhibits impaired GTP hydrolysis and enhances interaction with its effector ROCK. RHOAY42C mutation and Cdh1 loss induce actin/cytoskeletal rearrangements and activity of focal adhesion kinase (FAK), which activates YAP–TAZ, PI3K–AKT, and β-catenin. RHOAY42C murine models were sensitive to FAK inhibition and to combined YAP and PI3K pathway blockade. These results, coupled with sensitivity to FAK inhibition in patient-derived DGC cell lines, nominate FAK as a novel target for these cancers.
The functional significance of recurrent RHOA mutations in DGC has remained unresolved. Through biochemical studies and mouse modeling of the hotspot RHOAY42C mutation, we establish that these mutations are activating, detail their effects upon cell signaling, and define how RHOA-mediated FAK activation imparts sensitivity to pharmacologic FAK inhibitors.See related commentary by Benton and Chernoff, p. 182.This article is highlighted in the In This Issue feature, p. 161